MRNA 코로나19 예방접종에 따른 심근염 및/또는 심낭염 국가 감시 연구 (MYCOVACC)
Myocarditis is inflammation of the heart muscle. Pericarditis is inflammation of the lining surrounding the heart muscle. Symptoms of these conditions can include pain in the chest and rapid or irregular heartbeat. There are many different causes for myocarditis and pericarditis including COVID-19 infection.
The MYCOVACC study will identify patients using local screening strategies, including research communications, care provider referrals, and medical record review. The retrospective component of the study will collect information about patients suffering from vaccine associated myopericarditis and COVID-19 associated myopericarditis. Consenting patients will then be prospectively followed according to standard of care protocols. The main objectives of MYCOVACC are to describe the rate of major adverse cardiovascular events, functional outcomes including quality of life, and myocardial recovery through imaging.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Jenny Petterson, MSc
- 전화번호: 604-875-5104
- 이메일: jenny.petterson@vch.ca
연구 연락처 백업
- 이름: Naomi Uchida, RN
- 전화번호: 604-875-5324
- 이메일: naomi-uchida@ubc.ca
연구 장소
-
-
British Columbia
-
Vancouver, British Columbia, 캐나다, V5Z 1M9
- 모병
- Vancouver General Hospital
-
연락하다:
- Jenny Petterson, MSc
- 전화번호: 604 - 875 - 5104
- 이메일: jenny.petterson@vch.ca
-
수석 연구원:
- Nathaniel Hawkins, MD
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
- 어린이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Patients who have suffered or are suffering from 1) COVID-19 infection associated myocarditis, 2) COVID-19 infection associated pericarditis, 3) COVID-19 vaccine associated myocarditis, 4) COVID-19 vaccine associated pericarditis, 5) Alternative etiology myocarditis, 6) Alternative etiology pericarditis
Definition of myocarditis and pericarditis follows standard clinical definition as outlined in "Brighton Collaboration myocarditis case definition and levels of diagnostic certainty 1,2 and 3"
설명
Inclusion Criteria:
-
Inclusion criteria for vaccine associated myocarditis/pericarditis.
-
COVID-19 vaccination within previous 42 days. AND
-
At least one cardiac symptom of suspected myocarditis/pericarditis (Appendix 5).
OR At least two non-specific symptoms (Appendix 5). OR In infants and young children, at least two non-specific pediatric symptoms (Appendix 5).
OR No symptoms, but abnormal histopathology or a combination of abnormal cardiac biomarkers with abnormal cardiac imaging (echo or MRI).
AND
-
At least one of the following objective findings (Brighton Criteria case definitions, Appendices 1 to 5):
- Histopathologic examination of myocardial tissue (autopsy or endomyocardial biopsy) showed myocardial inflammation.
- Elevated myocardial biomarker (Troponin T, Troponin I, or CK-MB).
- Cardiac MRI abnormality.
- Echocardiographic abnormality.
- New or worsening arrhythmia on electrocardiogram, Holter monitor, or telemetry.
- Elevated inflammation biomarkers: erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), hs-CRP, or D-Dimer.
- Physical examination pericardial friction rub or pulsus paradoxus.
- Pericardial fluid or inflammation by imaging (echo, MRI, or CT).
- Enlarged heart on chest radiograph.
AND
-
No alternative cause of presentation. e.g. infectious or autoimmune myocarditis.
-
-
Inclusion criteria for COVID-19 associated myocarditis/pericarditis
-
COVID-19 infection within the previous 42 days.
AND
-
Myocarditis/pericarditis as per Brighton Criteria for vaccine associated myocarditis/pericarditis.
AND
-
No alternative cause of presentation.
-
Inclusion criteria alternative etiology myocarditis.
-
Myocarditis/pericarditis as per Brighton Criteria for vaccine associated myocarditis/pericarditis.
AND
-
No alternative cause of presentation.
Exclusion Criteria:
- For prospective invitation and follow-up, inability to provide informed consent. Consent will be sought from patients or their authorised substitute decision maker.
- Patients not fulfilling Brighton Criteria levels 1-3 will be excluded if they are level 4 (insufficient evidence for myocarditis) or Level 5 (not myocarditis) or have an alternative diagnosis such as myocardial infarction.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: PROSPECTIVE
그룹/코호트 수
코호트 및 개입
그룹/코호트그룹/코호트 |
개입 / 치료개입 / 치료 |
|---|---|
|
mRNA COVID-19 vaccine associated myocarditis
Participants who had developed myocarditis within 42 days of getting a mRNA COVID-19 vaccine |
Stand of care ECG, Holter, MRI, ECHO, Quality of life questionnaire will be used to follow the clinical outcomes and patient reported outcomes to assess for study objectives |
|
mRNA COVID-19 vaccine associated pericarditis
Participants who had developed pericarditis within 42 days of getting a mRNA COVID-19 vaccine |
Stand of care ECG, Holter, MRI, ECHO, Quality of life questionnaire will be used to follow the clinical outcomes and patient reported outcomes to assess for study objectives |
|
COVID-19 infection associated myocarditis
Participants who had developed myocarditis within 42 days of being infected with the SARS-COV-2 virus |
Stand of care ECG, Holter, MRI, ECHO, Quality of life questionnaire will be used to follow the clinical outcomes and patient reported outcomes to assess for study objectives |
|
COVID-19 infection associated pericarditis
Participants who had developed pericarditis within 42 days of being infected with the SARS-COV-2 virus |
Stand of care ECG, Holter, MRI, ECHO, Quality of life questionnaire will be used to follow the clinical outcomes and patient reported outcomes to assess for study objectives |
|
Alternative etiology myocarditis
Any participants with myocarditis that is not associated with the mRNA COVID-19 vaccine or SARS-COV-2 viral infection |
Only baseline quality of life questionnaires will be utilized in the alternative etiology myocarditis cohort as they will not be followed up in the study |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Composite Major Adverse Cardiac Event (MACE) at 30 days post vaccination (preferred by cardiovascular community) and at 42 days post vaccination (preferred by vaccine monitoring investigators)
기간: From date of vaccination and up to 3 years
|
Including any of:
|
From date of vaccination and up to 3 years
|
|
Recovery of cardiac function in patients with previously documented abnormal cardiac function
기간: Through study completion, an average of 3 years
|
Patients with Left Ventricular Ejection Fraction (LVEF)<55% during anytime at baseline, with LVEF increase by 5% from worst baseline measurement |
Through study completion, an average of 3 years
|
|
Quality of life using validated instruments at baseline, 3 months, 12 months, and annually
기간: Through study completion, an average of 3 years
|
Quality of life: EQ-5D-5L questionnaire for adults or EQ-5D-Y questionnaire for children. |
Through study completion, an average of 3 years
|
|
Depression and anxiety using validated instruments at baseline, 3 months, 12 months, and annually
기간: Through study completion, an average of 3 years
|
Depression and anxiety data: PHQ-9 and GAD-7. |
Through study completion, an average of 3 years
|
|
Physical activity using validated instruments at baseline, 3 months, 12 months, and annually
기간: Through study completion, an average of 3 years
|
Physical activity: International Activity Questionnaire. |
Through study completion, an average of 3 years
|
2차 결과 측정
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
MRNA 코로나19 백신 접종 후 30일과 42일의 1차 복합 평가변수의 개별 구성요소는 무엇입니까?
기간: 예방접종일로부터 3년까지
|
예방접종일로부터 3년까지
|
|
MRNA 코로나19 백신 접종 후 심방부정맥 발생률은?
기간: 예방접종일로부터 3년까지
|
예방접종일로부터 3년까지
|
|
MRNA 코로나19 백신 접종 후 전체 원인 및 심혈관 사망률은?
기간: 예방접종일로부터 3년까지
|
예방접종일로부터 3년까지
|
|
MRNA 코로나19 백신 접종 후 전체 원인 및 심혈관계 입원율은?
기간: 예방접종일로부터 3년까지
|
예방접종일로부터 3년까지
|
|
MRNA 코로나19 백신 접종 후 심근염/심낭염 재발률은?
기간: 예방접종일로부터 3년까지
|
예방접종일로부터 3년까지
|
|
MRNA 코로나19 백신 접종 후 협착성 심낭염 발병률은?
기간: 예방접종일로부터 3년까지
|
예방접종일로부터 3년까지
|
공동 작업자 및 조사자
수사관
수사관
- 수석 연구원: Nathaniel Hawkins, MD, Vancouver General Hospital
간행물 및 유용한 링크
유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- MYCOVACC
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .